Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma

Gwad, Asmaa Abd El; Matboli, Marwa; El-Tawdi, Ahmed Hassan Fawzi; Habib, Eman K.; Shehata, Hanan H.; Ibrahim, Doaa; Tash, Fathy

doi:10.1002/jcb.27109

Cited by 52 publications

(40 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abd El Gwad et al found that lncRNA RP11-513I15.6 and miR-1262 are included in the RAB11A competing endogenous network [104]. These exosomal RNA-based biomarkers showed good sensitivity and specificity in distinguishing HCC from HCV and healthy controls.…”

Section: Noncoding Rna In Exosomesmentioning

confidence: 99%

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside

Sasaki

Kanda

Yokosuka

et al. 2019

IJMS

View full text Add to dashboard Cite

As hepatocellular carcinoma (HCC) usually occurs in the background of cirrhosis, which is an end-stage form of liver diseases, treatment options for advanced HCC are limited, due to poor liver function. The exosome is a nanometer-sized membrane vesicle structure that originates from the endosome. Exosome-mediated transfer of proteins, DNAs and various forms of RNA, such as microRNA (miRNA), long noncoding RNA (lncRNA) and messenger RNA (mRNA), contributes to the development of HCC. Exosomes mediate communication between both HCC and non-HCC cells involved in tumor-associated cells, and several molecules are implicated in exosome biogenesis. Exosomes may be potential diagnostic biomarkers for early-stage HCC. Exosomal proteins, miRNAs and lncRNAs could provide new biomarker information for HCC. Exosomes are also potential targets for the treatment of HCC. Notably, further efforts are required in this field. We reviewed recent literature and demonstrated how useful exosomes are for diagnosing patients with HCC, treating patients with HCC and predicting the prognosis of HCC patients.

show abstract

Section: Noncoding Rna In Exosomesmentioning

confidence: 99%

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside

Sasaki

Kanda

Yokosuka

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Moreover, some recent studies revealed that panels consisting of ncRNAs and their related ceRNETs can also be used as diagnostic biomarkers for HCC. Asmaa et al [156] constructed an lncRNA-associated ceRNET (lncRNA-RP11-513I15.6-miR1262-RAB11A mRNA) according to an in silico analysis, followed by validation in serum specimens and additional clinical and experimental assays. Receiver operating characteristic curve analysis revealed that RAB11A mRNA, lncRNA-RP11-513I15.6 and miR-1262 in the ceRNET were effective biomarkers to differentiate HCC subjects from healthy controls (area under curve: 0.963, 0.847 and 0.822, respectively).…”

Section: Potential Diagnostic Biomarkers In Hccmentioning

confidence: 99%

“…Several ncRNAs that act as ceRNAs have been identified in the circulation and other body fluids in HCC and other cancers [ 108 , 156 – 158 ]. These results suggested the potential that ncRNAs that act as ceRNAs and their associated ceRNETs may be useful for clinical applications as diagnostic biomarkers of HCC (Table 5 ).…”

Section: The Clinical Application Of Ncrnas As Cernas In Hccmentioning

confidence: 99%

“…Receiver operating characteristic curve analysis revealed that RAB11A mRNA, lncRNA-RP11-513I15.6 and miR-1262 in the ceRNET were effective biomarkers to differentiate HCC subjects from healthy controls (area under curve: 0.963, 0.847 and 0.822, respectively). Moreover, the combination of serum exosomal miR-1262, lncRNARP11-513I15.6 and AFP measurements improved the diagnostic accuracy to detect HCC at the early stage to nearly 100% sensitivity and 76.7% accuracy [ 156 ]. With the development of specific algorithms for ncRNA detection and quantification, we believe that more and more ncRNAs that function as ceRNAs will be identified as diagnostic biomarkers for HCC.…”

Section: The Clinical Application Of Ncrnas As Cernas In Hccmentioning

confidence: 99%

See 1 more Smart Citation

The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma

Xiao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Accumulating evidence has emerged revealing that noncoding RNAs (ncRNAs) play essential roles in the occurrence and development of hepatocellular carcinoma (HCC). However, the complicated regulatory interactions among various ncRNAs in the development of HCC are not entirely understood. The newly discovered mechanism of competing endogenous RNAs (ceRNAs) uncovered regulatory interactions among different varieties of RNAs. In recent years, a growing number of studies have suggested that ncRNAs, including long ncRNAs, circular RNAs and pseudogenes, play major roles in the biological functions of the ceRNA network in HCC. These ncRNAs can share microRNA response elements to affect microRNA affinity with target RNAs, thus regulating gene expression at the transcriptional level and both physiological and pathological processes. The ncRNAs that function as ceRNAs are involved in diverse biological processes in HCC cells, such as tumor cell proliferation, epithelial-mesenchymal transition, invasion, metastasis and chemoresistance. Based on these findings, ncRNAs that act as ceRNAs may be promising candidates for clinical diagnosis and treatments. In this review, we discuss the mechanisms and research methods of ceRNA networks. We also reviewed the recent advances in studying the roles of ncRNAs as ceRNAs in HCC and highlight possible directions and possibilities of ceRNAs as diagnostic biomarkers or therapeutic targets. Finally, the limitations, gaps in knowledge and opportunities for future research are also discussed.

show abstract

“…With the advances in next-generation sequencing, an increasing number of circRNAs have recently been unveiled. [4][5][6] Recently, it has been reported that abundant conserved miRNA response elements (MREs) exist in circRNAs, 7 making circRNAs a hot topic in ceRNA family research. 3 Competing endogenous RNAs (ceRNAs) compete with other RNAs for the seed region of shared miRNAs, thus modulating the activity of the miRNAs.…”

Section: Introductionmentioning

confidence: 99%

Construction of a circRNA‐miRNA‐mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma

Xiao

2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background Many studies focusing on circular RNAs (circRNAs) have recently been published. However, a large number of circRNAs remain to be explored. This study was designed to discover new circRNAs and investigate their potential roles in the pathogenesis of pancreatic ductal adenocarcinoma (PDAC). Methods A combination of gene chip analysis and bioinformatic methods was utilized to reveal new circRNAs and their possible mechanisms in PDAC. A circRNA‐miRNA‐mRNA network was established based on the results of differential analyses and interaction predictions. Promising drugs for treating PDAC were determined by connectivity map (CMap) analysis. Results Expression profile data were collected from the Gene Expression Omnibus database, and integration of differentially expressed circRNAs (DECs) from two gene chips using the RobustRankAggreg method revealed 10 DECs. The microRNA (miRNA) response elements of these 10 DECs were predicted. The predicted miRNAs and differentially expressed miRNAs were intersected, and 12 overlapping miRNAs were acquired. Next, 2908 miRNA target mRNAs and 1187 differentially expressed genes (DEGs) in PDAC were identified and combined, revealing 118 overlapping mRNAs. A protein‐protein interaction network was constructed with the 118 mRNAs, and four hub genes (CDH1, SERPINE1, IRS1 and FYN) were identified. Using Gene Expression Profiling Interactive Analysis, survival analyses were conducted for the four hub genes, and SERPINE1 and FYN were found to be significantly associated with PDAC patient survival. Functional enrichment analysis indicated that these four hub genes are closely associated with certain cancer‐related biological functions and pathways. In addition, CMap analysis based on the four hub genes was performed to screen potential therapeutic agents for PDAC, and three bioactive chemicals (celastrol, 5109870 and MG‐132) were discovered. Conclusions The results of this study further our understanding of the pathogenesis and treatment of PDAC from the perspective of the circRNA‐related competing endogenous RNA network.

show abstract

Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma

Cited by 52 publications

References 47 publications

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside

The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma

Construction of a circRNA‐miRNA‐mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About